Pegvaliase
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB12839 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 34 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | diabetic retinopathy | KG + DL |
| 2 | severe nonproliferative diabetic retinopathy | KG + DL |
| 3 | diabetic cataract | KG + DL |
| 4 | cortical cataract | KG + DL |
| 5 | nuclear senile cataract | KG + DL |
| 6 | immature cataract | KG + DL |
| 7 | craniostenosis cataract | KG + DL |
| 8 | tetanic cataract | KG + DL |
| 9 | mature cataract | KG + DL |
| 10 | diabetes mellitus type 2 associated cataract | KG + DL |
| 11 | senile cataract | KG + DL |
| 12 | bronchitis | KG + DL |
| 13 | microvascular complications of diabetes, susceptibility to | KG + DL |
| 14 | bronchial neoplasm (disease) | KG + DL |
| 15 | idiopathic bronchiectasis | KG + DL |
| 16 | infective urethral stricture | KG + DL |
| 17 | hemorrhagic disease of newborn | KG + DL |
| 18 | Chagas cardiomyopathy | KG + DL |
| 19 | post-bacterial disorder | KG + DL |
| 20 | postinfectious vasculitis | KG + DL |
| 21 | post-infectious syndrome | KG + DL |
| 22 | otitis externa | KG + DL |
| 23 | infection-related hemolytic uremic syndrome | KG + DL |
| 24 | diffuse gastric adenocarcinoma | KG + DL |
| 25 | corneal neovascularization | KG + DL |
| 26 | ductal or ductular proliferation | KG + DL |
| 27 | bronchial adenomas/carcinoids childhood | KG + DL |
| 28 | chondroid hamartoma | KG + DL |
| 29 | non-seminomatous lesion | KG + DL |
| 30 | tumor of testis and paratestis | KG + DL |
| 31 | neuromuscular junction disease | KG + DL |
| 32 | gastric adenocarcinoma and proximal polyposis of the stomach | KG + DL |
| 33 | thyroglossal duct cyst | KG + DL |
| 34 | odontogenic cyst | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.